Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19432962 | 0.89 | TP53 (0.48) | BRD4CREBBPTP53MAPTTHRB | |
| SCHEMBL19423620 | 0.79 | USP2 (0.51) | BRD4CREBBPTHRBMEN1KMT2A | |
| SCHEMBL30336298 | 0.77 | BRD4 (0.44) | BRD4CREBBPTP53MAPTALDH1A1 | |
| SCHEMBL24508983 | 0.77 | BRD4 (0.44) | BRD4CREBBPTP53MAPTALDH1A1 | |
| SCHEMBL20169598 | 0.77 | BRD4 (0.44) | BRD4CREBBPMAPTTHRBALDH1A1 | |
| SCHEMBL19419343 | 0.75 | BRD4 (0.43) | BRD4CREBBPALDH1A1MEN1KMT2A | |
| SCHEMBL5518583 | 0.74 | KMT2A (0.65) | BRD4MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17027134 | 0.74 | BRD4 (0.43) | BRD4CREBBPMAPTALDH1A1MEN1 | |
| SCHEMBL3249363 | 0.73 | PARP1 (0.62) | TP53MAPTTHRBALDH1A1MEN1 | |
| SCHEMBL9452091 | 0.73 | BRD4 (0.40) | BRD4CREBBPMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436449-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-9975902-B2 | Compounds for the inhibition of cyclophilins and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| WO-2017173052-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | PPIG, PPIH, FKBP2 | BRD4 3961/4885CREBBP 960/4885TP53 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.